title: Will fixing the vasoactivity caused by hemoglobin-based oxygen carriers be enough?
authors.forename: Pedro
authors.initials: P
authors.lastname: Cabrales
authors.forename: Amy G
authors.initials: AG
authors.lastname: Tsai
mesh_terms: D000818:Animals; D001802:Blood Substitutes / Q000009:adverse effects*; D006454:Hemoglobins / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D014661:Vasoconstriction / Q000187:drug effects*
chemical_list: D001802:Blood Substitutes; D006454:Hemoglobins; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D009569:Nitric Oxide